![logo](/logos/MORF.webp)
Morphic Holding, Inc.
NASDAQ:MORF
56.99 (USD) • At close August 15, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Morphic Holding, Inc. |
Symbool | MORF |
Munteenheid | USD |
Prijs | 56.99 |
Beurswaarde | 2,862,305,653 |
Dividendpercentage | 0% |
52-weken bereik | 19.345 - 57 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Praveen P. Tipirneni M.D. |
Website | https://www.morphictx.com |
An error occurred while fetching data.
Over Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)